Golden
ImStar Therapeutics

ImStar Therapeutics

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien, Professor and Senior Canada Research Chair at Université Laval. ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. 



Pipeline

The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases. The ALS therapeutic target TDP-43, also called TANA (TDP-43 Associated NF-κB Activation) is based on the research of Dr. Julien at Université Laval.



IMS-088 was considered their lead drug development program in 2016. The compound was designed to target a key immune system activation pathway involved in neurodegeneration. IMS-088 was derived from withaferin A, a natural compound isolated from the leaves of the winter cherry plant Withania somnifera. Withaferin A in preclinical studies showed improvements in function and extended survival but lacked certain characteristics that would make it optimal for drug development. The compound IMS-088 was designed by ImStar chemists to have improved drug-like properties and to be potent and safe in preclinical studies.



Funding

Seed Round

On June 8, 2016 ImStar Therapeutics closed their seed funding round with $1.8 million in funding from BDC Venture Capital and Accel-Rx Health Sciences Accelerator. 



Timeline

People

Name
Role
LinkedIn

Agnes Chan

COO



Daniel Wattier

Co-Founder & CEO



David Hunt

Senior Vice President, Research and Development



Jean Pierre Julien

Co-Founder & CSO



Jeff Charpentier

CFO



Julia Levy

Board Chair



Further reading

Title
Author
Link
Type
Date

ImStar Therapeutics raises $1.8 million to research ALS treatment solutions | BetaKit

JESSICA GALANG

Web



ImStar Therapeutics Selects Lead Drug Candidate for ALS

ImStar Therapeutics

News



StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

StemCells, Inc.

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References